Unstable angina non ST elevation myocardial infarction anticoagulant therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 12: | Line 12: | ||
# Anticoagulant therapy should be added to [[antiplatelet therapy]] in [[UA]] / [[NSTEMI]] patients as soon as possible after presentation. | # Anticoagulant therapy should be added to [[antiplatelet therapy]] in [[UA]] / [[NSTEMI]] patients as soon as possible after presentation. | ||
::a. For patients in whom an invasive strategy is selected, regimens with established efficacy at a ''Level of Evidence: A'' include [[enoxaparin]] and [[UFH]], and those with established efficacy at a '' | ::a. For patients in whom an invasive strategy is selected, regimens with established efficacy at a ''Level of Evidence: A'' include [[enoxaparin]] and [[UFH]], and those with established efficacy at a ''Level of Evidence: B'' include [[bivalirudin]] and [[fondaparinux]]. | ||
::b. For patients in whom a conservative strategy is selected, regimens using either [[enoxaparin]] or [[UFH]] | ::b. For patients in whom a conservative strategy is selected, regimens using either [[enoxaparin]] or [[UFH]] (Level of Evidence: A) or [[fondaparinux]] (Level of Evidence: B) have established efficacy. | ||
::c. In patients in whom a conservative strategy is selected and who have an increased risk of bleeding, [[fondaparinux]] is preferable. | ::c. In patients in whom a conservative strategy is selected and who have an increased risk of bleeding, [[fondaparinux]] is preferable. (Level of Evidence: B) | ||
Revision as of 18:55, 18 May 2009
Cardiology Network |
![]() Discuss Unstable angina non ST elevation myocardial infarction anticoagulant therapy further in the WikiDoc Cardiology Network |
Adult Congenital |
---|
Biomarkers |
Cardiac Rehabilitation |
Congestive Heart Failure |
CT Angiography |
Echocardiography |
Electrophysiology |
Cardiology General |
Genetics |
Health Economics |
Hypertension |
Interventional Cardiology |
MRI |
Nuclear Cardiology |
Peripheral Arterial Disease |
Prevention |
Public Policy |
Pulmonary Embolism |
Stable Angina |
Valvular Heart Disease |
Vascular Medicine |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview of Anticoagulant Therapy in NSTEMI
ACC / AHA Guidelines (DO NOT EDIT) [1]
“ |
Class I
Class IIa
|
” |
Sources
- The ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Eleveation Myocardial Infarction [1]
References
- ↑ 1.0 1.1 Anderson JL, Adams CD, Antman EM; et al. (2007). "ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine". JACC. 50 (7): e1–e157. PMID 17692738. Text "doi:10.1016/j.jacc.2007.02.013 " ignored (help); Unknown parameter
|month=
ignored (help)